Article
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
Clinical pharmacology and therapeutics - 1 Aug 2018
Kim Hanna, Brooks Kristina M, Tang Cheng Cai, Wakim Paul, Blake Mary, Brooks Stephen R, Montealegre Sanchez Gina A, de Jesus Adriana A, Huang Yan, Tsai Wanxia Li, Gadina Massimo, Prakash Apurva, Janes Jonathan Marcus, Zhang Xin, Macias William L, Kumar Parag, Goldbach-Mansky Raphaela
Abstract excerpt
Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17 mg per day. Covariates of weight and renal function significantly influenced volume-of-distribution and clearance, respectively....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.